Trial Profile
Randomized Phase III Study of Intensive Chemotherapy With or Without Dasatinib (Sprycel) in Adult Patients With Newly Diagnosed Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 24 Mar 2024
Price :
$35
*
At a glance
- Drugs Dasatinib (Primary) ; Cytarabine; Daunorubicin; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 22 Feb 2024 Status changed from active, no longer recruiting to completed.
- 27 Apr 2021 Planned primary completion date changed from 1 Feb 2021 to 1 Feb 2024.
- 27 Apr 2021 Status changed from recruiting to active, no longer recruiting.